KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Exchange Rate Effect (2016 - 2025)

Historic Exchange Rate Effect for Acadia Pharmaceuticals (ACAD) over the last 15 years, with Q2 2025 value amounting to $24000.0.

  • Acadia Pharmaceuticals' Exchange Rate Effect rose 70000.0% to $24000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was -$41000.0, marking a year-over-year increase of 1086.96%. This contributed to the annual value of -$94000.0 for FY2024, which is 42222.22% down from last year.
  • As of Q2 2025, Acadia Pharmaceuticals' Exchange Rate Effect stood at $24000.0, which was up 70000.0% from -$5000.0 recorded in Q1 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Exchange Rate Effect registered a high of $24000.0 during Q2 2025, and its lowest value of -$60000.0 during Q4 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' median Exchange Rate Effect value was $1000.0 (recorded in 2021), while the average stood at -$4705.9.
  • Its Exchange Rate Effect has fluctuated over the past 5 years, first crashed by 95000.0% in 2024, then skyrocketed by 70000.0% in 2025.
  • Acadia Pharmaceuticals' Exchange Rate Effect (Quarter) stood at $1000.0 in 2021, then tumbled by 900.0% to -$8000.0 in 2022, then tumbled by 50.0% to -$12000.0 in 2023, then plummeted by 400.0% to -$60000.0 in 2024, then surged by 140.0% to $24000.0 in 2025.
  • Its last three reported values are $24000.0 in Q2 2025, -$5000.0 for Q1 2025, and -$60000.0 during Q4 2024.